Cargando…

Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial

BACKGROUND: Cigarette smoking has emerged as a leading cause of mortality among people with hepatitis C virus (HCV). People who inject drugs (PWID) represent the largest group of adults infected with HCV in the US. However, cigarette smoking remains virtually unexplored among this population. This s...

Descripción completa

Detalles Bibliográficos
Autores principales: Pericot-Valverde, Irene, Heo, Moonseong, Akiyama, Matthew J., Norton, Brianna L., Agyemang, Linda, Niu, Jiajing, Litwin, Alain H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718688/
https://www.ncbi.nlm.nih.gov/pubmed/33276738
http://dx.doi.org/10.1186/s12879-020-05667-3
_version_ 1783619540241874944
author Pericot-Valverde, Irene
Heo, Moonseong
Akiyama, Matthew J.
Norton, Brianna L.
Agyemang, Linda
Niu, Jiajing
Litwin, Alain H.
author_facet Pericot-Valverde, Irene
Heo, Moonseong
Akiyama, Matthew J.
Norton, Brianna L.
Agyemang, Linda
Niu, Jiajing
Litwin, Alain H.
author_sort Pericot-Valverde, Irene
collection PubMed
description BACKGROUND: Cigarette smoking has emerged as a leading cause of mortality among people with hepatitis C virus (HCV). People who inject drugs (PWID) represent the largest group of adults infected with HCV in the US. However, cigarette smoking remains virtually unexplored among this population. This study aimed at (1) determining prevalence and correlates of cigarette smoking among HCV-infected PWID enrolled in opiate agonist treatment programs; (2) exploring the association of smoking with HCV treatment outcomes including adherence, treatment completion and sustained virologic response (SVR); and 3) exploring whether cigarette smoking decreased after HCV treatment. METHODS: Participants were 150 HCV-infected PWID enrolled in a randomized clinical trial primarily designed to test three intensive models of HCV care. Assessments included sociodemographics, presence of chronic health and psychiatric comorbidities, prior and current drug use, quality of life, and HCV treatment outcomes. RESULTS: The majority of the patients (84%) were current cigarette smokers at baseline. There was a high prevalence of psychiatric and medical comorbidities in the overall sample of PWID. Alcohol and cocaine use were identified as correlates of cigarette smoking. Smoking status did not influence HCV treatment outcomes including adherence, treatment completion and SVR. HCV treatment was not associated with decreased cigarette smoking. CONCLUSIONS: The present study showed high prevalence of cigarette smoking among this population as well as identified correlates of smoking, namely alcohol and cocaine use. Cigarette smoking was not associated with HCV treatment outcomes. Given the detrimental effects that cigarette smoking and other co-occurring, substance use behaviors have on HCV-infected individuals’ health, it is imperative that clinicians treating HCV also target smoking, especially among PWID. The high prevalence of cigarette smoking among PWID will contribute to growing morbidity and mortality among this population even if cured of HCV. Tailored smoking cessation interventions for PWID along with HCV treatment may need to be put into clinical practice. TRIAL REGISTRATION: NCT01857245. Registered May 20, 2013.
format Online
Article
Text
id pubmed-7718688
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77186882020-12-07 Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial Pericot-Valverde, Irene Heo, Moonseong Akiyama, Matthew J. Norton, Brianna L. Agyemang, Linda Niu, Jiajing Litwin, Alain H. BMC Infect Dis Research Article BACKGROUND: Cigarette smoking has emerged as a leading cause of mortality among people with hepatitis C virus (HCV). People who inject drugs (PWID) represent the largest group of adults infected with HCV in the US. However, cigarette smoking remains virtually unexplored among this population. This study aimed at (1) determining prevalence and correlates of cigarette smoking among HCV-infected PWID enrolled in opiate agonist treatment programs; (2) exploring the association of smoking with HCV treatment outcomes including adherence, treatment completion and sustained virologic response (SVR); and 3) exploring whether cigarette smoking decreased after HCV treatment. METHODS: Participants were 150 HCV-infected PWID enrolled in a randomized clinical trial primarily designed to test three intensive models of HCV care. Assessments included sociodemographics, presence of chronic health and psychiatric comorbidities, prior and current drug use, quality of life, and HCV treatment outcomes. RESULTS: The majority of the patients (84%) were current cigarette smokers at baseline. There was a high prevalence of psychiatric and medical comorbidities in the overall sample of PWID. Alcohol and cocaine use were identified as correlates of cigarette smoking. Smoking status did not influence HCV treatment outcomes including adherence, treatment completion and SVR. HCV treatment was not associated with decreased cigarette smoking. CONCLUSIONS: The present study showed high prevalence of cigarette smoking among this population as well as identified correlates of smoking, namely alcohol and cocaine use. Cigarette smoking was not associated with HCV treatment outcomes. Given the detrimental effects that cigarette smoking and other co-occurring, substance use behaviors have on HCV-infected individuals’ health, it is imperative that clinicians treating HCV also target smoking, especially among PWID. The high prevalence of cigarette smoking among PWID will contribute to growing morbidity and mortality among this population even if cured of HCV. Tailored smoking cessation interventions for PWID along with HCV treatment may need to be put into clinical practice. TRIAL REGISTRATION: NCT01857245. Registered May 20, 2013. BioMed Central 2020-12-04 /pmc/articles/PMC7718688/ /pubmed/33276738 http://dx.doi.org/10.1186/s12879-020-05667-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Pericot-Valverde, Irene
Heo, Moonseong
Akiyama, Matthew J.
Norton, Brianna L.
Agyemang, Linda
Niu, Jiajing
Litwin, Alain H.
Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial
title Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial
title_full Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial
title_fullStr Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial
title_full_unstemmed Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial
title_short Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial
title_sort factors and hcv treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the prevail randomized clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718688/
https://www.ncbi.nlm.nih.gov/pubmed/33276738
http://dx.doi.org/10.1186/s12879-020-05667-3
work_keys_str_mv AT pericotvalverdeirene factorsandhcvtreatmentoutcomesassociatedwithsmokingamongpeoplewhoinjectdrugsonopioidagonisttreatmentsecondaryanalysisoftheprevailrandomizedclinicaltrial
AT heomoonseong factorsandhcvtreatmentoutcomesassociatedwithsmokingamongpeoplewhoinjectdrugsonopioidagonisttreatmentsecondaryanalysisoftheprevailrandomizedclinicaltrial
AT akiyamamatthewj factorsandhcvtreatmentoutcomesassociatedwithsmokingamongpeoplewhoinjectdrugsonopioidagonisttreatmentsecondaryanalysisoftheprevailrandomizedclinicaltrial
AT nortonbriannal factorsandhcvtreatmentoutcomesassociatedwithsmokingamongpeoplewhoinjectdrugsonopioidagonisttreatmentsecondaryanalysisoftheprevailrandomizedclinicaltrial
AT agyemanglinda factorsandhcvtreatmentoutcomesassociatedwithsmokingamongpeoplewhoinjectdrugsonopioidagonisttreatmentsecondaryanalysisoftheprevailrandomizedclinicaltrial
AT niujiajing factorsandhcvtreatmentoutcomesassociatedwithsmokingamongpeoplewhoinjectdrugsonopioidagonisttreatmentsecondaryanalysisoftheprevailrandomizedclinicaltrial
AT litwinalainh factorsandhcvtreatmentoutcomesassociatedwithsmokingamongpeoplewhoinjectdrugsonopioidagonisttreatmentsecondaryanalysisoftheprevailrandomizedclinicaltrial